What do systematic reviews say?

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 4614 participants
  Moderate

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1389 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1399 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1962 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1527 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1399 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 4930 participants
  Moderate

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1542 participants
  Very low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1399 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1962 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1527 participants
  Low

Intervention not reported

• Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 4930 participants
  Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs standard local care

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in major bleeding requiring transfusion of packed red blood cells compared with standard care (usual local haemostatic measures: gelatin sponge and…; GRADE not reported.

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes

  7 days
  RD 0.00 [-0.04, 0.04]
  2 studies · 125 participants
  GRADE not reported

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs standard local care

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in number of participants with postoperative bleedings requiring… compared with standard care (usual local haemostatic measures: gelatin sponge and… (moderate certainty).

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes

  7 days
  RD 0.02 [-0.07, 0.11]
  2 studies · 125 participants
  Moderate

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in number of minor postoperative bleeding episodes compared with placebo (placebo solution/mouthwash); GRADE not reported.

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes

  7 days
  RD -0.06 [-0.33, 0.20]
  2 studies · 128 participants
  GRADE not reported

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes

  7 days
  RD 0.00 [-0.04, 0.04]
  2 studies · 128 participants
  Moderate

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Aspirin vs placebo

The review found no eligible studies for this question.

• Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found